MEDI 0618
Alternative Names: MEDI-0618Latest Information Update: 25 Jun 2025
At a glance
- Originator AstraZeneca
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
- Discontinued Migraine
Most Recent Events
- 05 May 2025 Discontinued - Phase-I for Migraine in United Kingdom (Parenteral) (AstraZeneca pipeline, May 2025)
- 05 May 2025 Discontinued - Phase-II for Migraine (Treatment-experienced) in Spain, Poland, Netherlands, Italy, Hungary, Germany, Denmark, Czech Republic, USA (Parenteral) (AstraZeneca pipeline, May 2025)
- 07 Oct 2024 Phase-II clinical trials in Migraine (Treatment-experienced) in USA, Czech Republic, Denmark, Germany, Hungary, Netherlands, Italy, Poland, Spain (Parenteral) (NCT06602479)